Deng Huan, Rui Jun, Zhao Deyu, Liu Feng
Department of Respiratory Medicine, Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.
J Int Med Res. 2018 Jan;46(1):150-157. doi: 10.1177/0300060517716312. Epub 2017 Jul 31.
Objective To measure the rate of the A2063G mutation in the Mycoplasma pneumoniae ( M. pneumoniae) 23S rRNA domain V in children with pneumonia and to determine the correlation between radiographic findings and the presence of the A2063G mutation. Methods Patients who were hospitalized with a confirmed diagnosis of M. pneumoniae pneumonia were enrolled in this study. M. pneumoniae strains were collected for genotype analysis. Chest radiography was performed on all children prior to and following macrolide treatment. Clinical and imaging data were obtained. Results Of 211 patients, 195 (92.42%) harboured M. pneumoniae with the A2063G mutation. No significant differences were identified in inflammation score, chest radiography inflammation absorption grade before and after macrolide treatment, or pulmonary complications (atelectasis, hydrothorax, or pleuritis) prior to macrolide treatment when children were stratified based on the presence or absence of the A2063G mutation. Conclusions A high proportion of children with pneumonia harboured strains of M. pneumoniae with the A2063G mutation in the 23S rRNA domain V. However, no obvious chest radiographic features of M. pneumoniae pneumonia were associated with the A2063G variant.
目的 检测肺炎患儿肺炎支原体(M. pneumoniae)23S rRNA结构域V中A2063G突变的发生率,并确定影像学表现与A2063G突变存在之间的相关性。方法 本研究纳入确诊为肺炎支原体肺炎并住院治疗的患者。收集肺炎支原体菌株进行基因分型分析。所有儿童在大环内酯类药物治疗前后均进行胸部X线检查。获取临床和影像学数据。结果 211例患者中,195例(92.42%)携带具有A2063G突变的肺炎支原体。根据是否存在A2063G突变对儿童进行分层时,在大环内酯类药物治疗前后的炎症评分、胸部X线炎症吸收等级或大环内酯类药物治疗前的肺部并发症(肺不张、胸腔积液或胸膜炎)方面未发现显著差异。结论 肺炎患儿中很大一部分携带23S rRNA结构域V中具有A2063G突变的肺炎支原体菌株。然而,肺炎支原体肺炎的明显胸部影像学特征与A2063G变异无关。